Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.53 |
| ▸ | TRPM8 | Q7Z2W7 | 5/20 | 0.53 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.48 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.48 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2161022 | 0.90 | MEN1 (0.56) | NPC1RAB9ASMN1; SMN2PKMEPHX2 | |
| SCHEMBL24540478 | 0.84 | TRPM8 (0.49) | SMN1; SMN2TRPM8TRPV1HPGDCYP3A4 | |
| SCHEMBL2161053 | 0.84 | TRPM8 (0.50) | TRPM8TRPV1CYP3A4MEN1KMT2A | |
| SCHEMBL2159792 | 0.83 | TRPM8 (0.47) | SMN1; SMN2TRPM8EPHX1MEN1KMT2A | |
| SCHEMBL2159809 | 0.83 | KMT2A (0.54) | NPC1TRPM8MTNR1AMTNR1BTRPV1 | |
| SCHEMBL1629039 | 0.82 | TAAR1 (0.54) | EPHX2TRPM8EPHX1MEN1KMT2A | |
| SCHEMBL3392794 | 0.82 | TAAR1 (0.54) | EPHX2TRPM8EPHX1MEN1KMT2A | |
| SCHEMBL24540254 | 0.82 | TAAR1 (0.54) | EPHX2TRPM8EPHX1MEN1KMT2A | |
| SCHEMBL2160155 | 0.82 | TRPM8 (0.50) | SMN1; SMN2TRPM8HPGDEPHX1MEN1 | |
| SCHEMBL24540260 | 0.82 | TRPM8 (0.53) | TRPM8TRPV1EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8377422-B2 | Carboxamide derivatives having cooling properties | GIVAUDAN S.A. (CH) | 2013-02-19 | — | — | US | claimed |
| US-20110182833-A1 | Carboxamide Derivatives Having Cooling Properties | GIVAUDAN SA (CH) | 2011-07-28 | — | — | US | claimed |
| EP-2229352-A2 | CARBOXAMIDE DERIVATIVES HAVING COOLING PROPERTIES | Givaudan SA (CH) | 2010-09-22 | — | — | EP | claimed |
| WO-2009070910-A2 | CARBOXAMIDE DERIVATIEVES HAVING COOLING PROPERTIES | GIVAUDAN SA (CH) | 2009-06-11 | — | — | WO | claimed |
| US-8377422-B2 | Carboxamide derivatives having cooling properties | GIVAUDAN S.A. (CH) | 2013-02-19 | — | — | US | disclosed |
| US-20110182833-A1 | Carboxamide Derivatives Having Cooling Properties | GIVAUDAN SA (CH) | 2011-07-28 | — | — | US | disclosed |
| EP-2229352-A2 | CARBOXAMIDE DERIVATIVES HAVING COOLING PROPERTIES | Givaudan SA (CH) | 2010-09-22 | — | — | EP | disclosed |
| WO-2009070910-A2 | CARBOXAMIDE DERIVATIEVES HAVING COOLING PROPERTIES | GIVAUDAN SA (CH) | 2009-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110182833-A1 | Carboxamide Derivatives Having Cooling Properties | CPS1, NQO2, NDUFA2 | NPC1 2267/4885RAB9A 2168/4885SMN1; SMN2 1240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.